Literature DB >> 12660633

Is intralesional injection of OK-432 effective in the treatment of lymphangioma in children?

Nigel Hall1, Niyi Ade-Ajayi, Clive Brewis, Derek J Roebuck, Edward M Kiely, David P Drake, Lewis Spitz, Agostino Pierro.   

Abstract

BACKGROUND: Intralesional injection of OK-432 has been proposed as an effective treatment of lymphangioma. The aim of this study was to review our experience with OK-432 injection of lymphangioma and to identify factors associated with successful outcome.
METHODS: We made a case note review of 19 children who received OK-432 injection. Median duration of follow-up was 17 months.
RESULTS: Lesions were diagnosed antenatally in 4 children, at birth in 4 children, and between 1 month and 11 years in the remainder. Anatomic locations were head/neck in 14, axilla in 1, and multiple locations in 4. Median number of injections per child was 2 (range, 1 to 5). Disappearance of the lesion was achieved after OK-432 injection in 2 patients (11%) and a marked reduction in 5 (26%); all these lesions were in the head and neck. Lesions larger than 5 cm and those outside the head and neck region did not respond well to OK-432 injection. Fourteen children (74%) required surgical excision after injection. Complications of OK-432 injection included partial tracheal obstruction, fever, local inflammatory response, and abscess formation.
CONCLUSIONS: OK-432 injection was effective in approximately one third of children with lymphangioma. Lesions outside the head and neck and those larger than 5 cm are unlikely to respond to this therapy. Injection of lymphangioma surrounding the airways may be hazardous.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12660633     DOI: 10.1067/msy.2003.62

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  15 in total

1.  Sclerotherapy of cervical cysts with Picibanil (OK-432).

Authors:  Stephan Knipping; Gerrit Goetze; Kerstin Neumann; Marc Bloching
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-11-03       Impact factor: 2.503

Review 2.  [Sclerotherapy for cystic lesions of the head and neck region].

Authors:  S Knipping; G Goetze
Journal:  HNO       Date:  2008-03       Impact factor: 1.284

3.  OK-432 sclerotherapy of lymphatic malformation in the head and neck: factors related to outcome.

Authors:  Dong Wook Kim
Journal:  Pediatr Radiol       Date:  2014-02-26

4.  Further experience with OK-432 for lymphangiomas.

Authors:  C Luzzatto; R Lo Piccolo; F Fascetti Leon; G F Zanon; T Toffolutti; A Tregnaghi
Journal:  Pediatr Surg Int       Date:  2005-10-25       Impact factor: 1.827

5.  [Lymphatic malformations in the head and neck: experiences with sclerotherapy].

Authors:  S Knipping; V Bau
Journal:  HNO       Date:  2011-07       Impact factor: 1.284

6.  [Increasing abdominal pain caused by abdominal tumor in a 21-year-old female].

Authors:  J Jakob; K T Moesta; B Rau
Journal:  Chirurg       Date:  2005-02       Impact factor: 0.955

7.  Surgical management of intra-abdominal cystic lymphangioma. Report of 20 cases.

Authors:  Amin Makni; Faouzi Chebbi; Fadhel Fetirich; Rachid Ksantini; Heykal Bedioui; Mohamed Jouini; Montassar Kacem; Zoubeir Ben Safta
Journal:  World J Surg       Date:  2012-05       Impact factor: 3.352

8.  Treatment of lymphatic malformations of head and neck with OK-432 sclerotherapy induce systemic inflammatory response.

Authors:  Mervi Närkiö-Mäkelä; Teppo Mäkelä; Pia Saarinen; Päivi Salminen; Ilkka Julkunen; Anne Pitkäranta
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-07-16       Impact factor: 2.503

Review 9.  Update on hemangiomas and vascular malformations of the head and neck.

Authors:  Behfar Eivazi; Mircia Ardelean; Wolfgang Bäumler; Hans-Peter Berlien; Hansjörg Cremer; Ravindhra Elluru; Peter Koltai; Jan Olofsson; Gresham Richter; Bernhard Schick; Jochen A Werner
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-12-04       Impact factor: 2.503

10.  [Sclerotherapy with OK-432 for cystic tumors in the neck region].

Authors:  M Bloching; G Götze; M Passmann; K Neumann
Journal:  HNO       Date:  2005-03       Impact factor: 1.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.